Should Everyone Take Tirzepatide? (Obesity Doctor Reacts to Mike Israetel) скачать в хорошем качестве

Should Everyone Take Tirzepatide? (Obesity Doctor Reacts to Mike Israetel)

Should everyone take tirzepatide (Mounjaro, Zepbound)? In this video, obesity doctor Dr. Spencer Nadolsky reacts to Mike Israetel’s viral claim that “most adults should consider taking tirzepatide even if they aren’t overweight.” I break down the science behind tirzepatide, where the evidence is strong, and where we don’t yet have answers. We’ll cover the real risks, benefits, and whether GLP-1 medications make sense for people without obesity or type 2 diabetes. Then, I steelman the argument and explore potential future uses of tirzepatide beyond weight loss including PCOS, binge eating, alcohol use, inflammation, and even heart disease prevention. If you’re curious about whether these medications are right for you, or just want the no-nonsense breakdown of the latest GLP-1 hype, this video is for you. Work with me and my team at www.joinvineyard.com. 00:00 – Should GLP-1s be “in the water”? 00:25 – The problem with “evidence-based” claims 00:54 – What the trials actually tell us 02:04 – Are we in an evidence-free zone? 02:50 – What is clinical obesity really? 04:03 – Could most people benefit? 04:30 – Surprising off-label effects (alcohol, binge eating, PCOS) 06:55 – Autoimmune and heart health potential 08:18 – Should everyone really be on GLP-1s? 09:15 – Prevention, future uses, and my take Subscribe for more weight loss science, GLP-1 updates, and practical advice from a triple board-certified obesity specialist.